Trade Summary

3 days ago, Moat Ross, serving as COO at Kiniksa Pharmaceuticals International, Plc (KNSA), sold 2,367 shares at $48.58 per share, for a total transaction value of $114,989.00. Following this transaction, Moat Ross now holds 13,732 shares of KNSA.

This sale represents a 15.00% decrease in Moat Ross's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, April 6, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, April 8, 2026, 2 days after the trade was made.

Kiniksa Pharmaceuticals International, Plc operates in the HEALTHCARE sector, specifically within the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.